ZFP28 Activators
ZFP28 operate through various biochemical pathways to enhance its role in transcriptional regulation. Forskolin, by directly stimulating adenylate cyclase, elevates cAMP levels within the cell, leading to the activation of protein kinase A (PKA). This activation can phosphorylate transcription factors that interact with ZFP28, thereby enhancing its regulatory functions. Similarly, IBMX acts to sustain elevated cAMP levels by inhibiting phosphodiesterases, which usually degrade cAMP. This amplification of the cAMP signal leads to a prolonged activation of PKA, which can also bolster the transcriptional regulatory activities of ZFP28. Epinephrine interacts with adrenergic receptors that trigger a cascade resulting in increased cAMP production, again leading to the activation of PKA and subsequent enhancement of ZFP28's activity. Prostaglandin E2 (PGE2) and Isoproterenol work through their respective G-protein-coupled receptors to raise cAMP levels, fostering a similar outcome on PKA activity and ZFP28 function.
Rolipram and Zaprinast selectively inhibit phosphodiesterases 4 and 5 respectively, preventing cAMP breakdown, thereby indirectly promoting PKA activation and the enhancement of ZFP28's transcriptional regulation. Glucagon, through its receptor interaction, also leads to an increase in cAMP and subsequent PKA activation, which may particularly impact ZFP28's role in gene regulation pertinent to glucose metabolism. Cholera toxin, in contrast, leads to a continuous activation of the Gs alpha subunit, resulting in an unabated increase in cAMP and sustained PKA activation, which may significantly amplify ZFP28's transcriptional regulatory effects. Anisomycin, while not directly involved in the cAMP pathway, activates stress response pathways that can phosphorylate transcription factors and may intersect with ZFP28's regulatory pathways. Dibutyryl-cAMP and Sp-5,6-DCl-cBIMPS, as cAMP analogs, permeate the cell membrane and activate PKA, thereby providing another route to enhance ZFP28's transcriptional regulatory activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, which prevents the breakdown of cAMP and potentiates its action. The resultant rise in cAMP levels leads to activation of PKA, potentially enhancing the transcriptional regulatory activity of ZFP28. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine binds to adrenergic receptors, which can lead to an increase in intracellular cAMP levels via G-protein coupled receptor signaling, activating PKA and potentially enhancing ZFP28's transcriptional activity. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) interacts with its G-protein-coupled receptors, leading to increased cAMP production. This activation of cAMP/PKA signaling may enhance ZFP28's function in the nucleus. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is an agonist for beta-adrenergic receptors, stimulating the production of cAMP and activation of PKA. This could enhance ZFP28 activity by promoting transcriptional regulation through PKA signaling. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4, which increases intracellular cAMP levels by preventing its degradation. The cAMP-dependent pathway activation may increase the transcriptional regulatory functions of ZFP28. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor, which can lead to the activation of stress response pathways that may phosphorylate and activate transcription factors associated with ZFP28's regulatory functions. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl-cAMP is a cell-permeable cAMP analog that activates PKA. The activation of PKA may enhance ZFP28's transcriptional regulatory activity. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is a selective inhibitor of phosphodiesterase 5, which increases cAMP and cGMP levels. The increase in cAMP can activate PKA, which in turn may enhance the transcriptional regulatory activity of ZFP28. | ||||||